15 results about "Artesunate" patented technology

The invention discloses a manganese urate material, a gel preparation and application thereof, and relates to the technical field of gel preparations. The manganese urate material provided by the invention can enhance anti-tumor immune response, and has good application prospects of adjuvants, vaccines and medicines. Besides, the invention also provides a gel preparation, the preparation is a multifunctional temperature-sensitive hydrogel preparation taking poloxamer as a matrix, and the preparation is combined with artesunate, adriamycin, uric acid and manganese to realize efficient treatment of various tumors such as breast cancer and inhibit postoperative recurrence of the tumors.

This invention discloses a butyrate prodrug co-assembled with artesunate, its preparation method, and its application in kidney diseases, belonging to the field of biomedical technology. The invention first uses docosahexaenoic acid (DHA) as a hydrophobic framework, coupling it with 2,2'-dithiodiethanol to introduce disulfide bonds, and then grafts butyrate via esterification to obtain a butyrate prodrug. The butyrate prodrug and artesunate self-assemble through non-covalent interactions to obtain a co-assembled drug in nanoparticle form. This nanomedicine possesses excellent long-term in vivo circulation and passive targeted accumulation in the kidneys, and can achieve targeted drug release in response to the high-glutathione microenvironment within lesion cells. The two active ingredients synergistically exert metabolic regulation, anti-inflammatory, and antioxidant effects, inhibiting kidney inflammation and oxidative stress at multiple targets, protecting renal tubular epithelial cells, and effectively intervening in the pathological process of acute kidney injury. Furthermore, this drug has high biosafety, is simple to prepare, and is easy to scale up, showing broad application prospects in the prevention and treatment of kidney diseases.

This application discloses the use of artesunate in the preparation of drugs for enhancing the therapeutic effect of PARP inhibitors, belonging to the field of biomedical technology. The artesunate described in this application is a sesquiterpene lactone derivative extracted from the traditional Chinese medicine Artemisia annua. It has an inhibitory effect on the proliferation of BRCA wild-type ovarian cancer cells and low toxicity to normal human ovarian epithelial cells. This application's research found that artesunate can enhance the DNA damage and apoptosis induced by PARP inhibitors (such as olaparib, niraparib, and rucaparib), and improve the sensitivity of PARP inhibitors to BRCA wild-type ovarian cancer.

The invention relates to a pharmaceutical composition in the form of a spheroid dosage form that can be absorbed by oral route, said spheroid containing, as the sole active ingredient with antimalarial activity, a therapeutically effective amount of at least 200 mg of artesunate, for use as a drug.

The invention discloses application of artesunate in preparation of a PRMT1 inhibitor and / or an alpha-ketoglutaric acid supplement, and relates to the technical field of biological medicines. It is found through experiments that artesunate can target and inhibit the activity of arginine methyltransferase of PRMT1, inhibit methylation modification of downstream molecules IDH2 of PRMT1 and reduce expression of the downstream molecules IDH2, and then mitochondrial metabolic disorder in cancer cells is induced, including accumulation of various metabolites such as alpha-ketoglutaric acid. Therefore, a new application of artesunate is provided, and artesunate is used for preparing a PRMT1 inhibitor and / or an alpha-KG supplement. In addition, it is verified that artesunate can significantly inhibit tumor growth of multiple tumor-bearing mice and promote anti-tumor immunity, and artesunate can be used as a PRMT1 inhibitor and / or an alpha-KG supplement to prepare anti-tumor immunotherapy drugs.

The invention discloses an application of artesunate in preparation of a medicine for treating ureteral fibrosis after ureteral obstruction, and finds and verifies that artesunate can inhibit ureteral fibrosis and relieve hydronephrosis in an animal model of ureteral obstruction for the first time. A new direction is provided for research and development of ureteral fibrosis treatment medicines, artesunate is expected to become a safer and more effective medicine for treating ureteral fibrosis, and the artesunate has a wide application prospect in the field of ureteral fibrosis treatment.

The present invention describes a method of treating individuals suffering from microbial infections, including a parasitic disease such as malaria, by using an improved Artemisinin Combination Therapy (ACT), known as ActRx Tri-ACT Plus. The improved ACT therapy includes administering a combination of four drugs. In one embodiment of the present invention, the method includes administering to an individual a first composition comprising a therapeutically effective amount of an artemether spray sublingually. The individual is then administered a second composition, a therapeutically effective amount of artesunate. A third composition, an effective amount of berberine, or its pharmaceutically acceptable derivatives or salts is administered to the individual. A fourth composition, an effective amount of primaquine, or its pharmaceutically acceptable derivatives or salts is administered to the individual.

The invention discloses a pharmaceutical composition of artesunate combined with Xuebijing and application of the pharmaceutical composition, and relates to the technical field of pharmacy, effective components of the pharmaceutical composition comprise artesunate and Xuebijing injection, and application of the artesunate and Xuebijing injection in preparation of drugs for treating cerebral malaria. According to the application disclosed by the invention, the artesunate combined with Xuebijing has a remarkable treatment effect on experimental cerebral malaria mice, and the expression of NO is improved by activating a VEGF / Akt / eNOS signal channel, so that liver, spleen and brain tissues are protected, the immune function is recovered, and the survival rate is further improved. The research provides a new drug combination strategy for clinical treatment of cerebral malaria, and lays a theoretical foundation for deep understanding of the action mechanism of cerebral malaria.

The present invention relates to the use of artesunate for the prevention or treatment of chemotherapeutic drug induced cardiotoxicity. Artesunate improves the cardiac function of a mouse with chemotherapeutic drug induced cardiotoxicity; the chemotherapeutic drug-induced myocardial injury can be repaired, and the chemotherapeutic drug-induced myocardial fibrosis can be inhibited; the content of myocardial injury markers creatine kinase and lactic dehydrogenase in body serum can be reduced.

The invention discloses a nano self-assembly body capable of reducing allograft rejection. The nano self-assembly body is a nano particle obtained by self-assembling an artesunate-mycophenolic acid ester self-assembly body prodrug and DSPE-PEG2000, wherein the artesunate-mycophenolic acid ester self-assembly body prodrug and the DSPE-PEG2000 are of the following structure. The invention also discloses a preparation method and application of the nano self-assembly body. In addition, the invention also discloses a structure and a preparation method of the artesunate-mycophenolate self-assembly prodrug. In the preparation process of the nano self-assembly, artesunate and mycophenolic acid ester are synthesized into a prodrug through esterification reaction, and then the prodrug is combined with DSPE-PEG2000 to prepare the nano drug. The nano-drug has the characteristic of accurately targeting the spleen, and can effectively remodel the immune microenvironment after transplantation. Through research and development of the nano-drug, the problem of toxic and side effects caused by long-term use of a traditional immunosuppressor and the problem of poor treatment effect of a natural small-molecule immunosuppressor are successfully solved, and the nano-drug shows extremely wide development prospects and huge potential in the field of future clinical application.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to an artesunate nanosuspension and a preparation method thereof, artesunate is used as an active pharmaceutical ingredient, and the content of artesunate is 0.1-10% (w / v); the dispersing agent is selected from one or more of polyvinyl alcohol, povidone, lauryl sodium sulfate, poloxamer and the like, and the content of the dispersing agent is 0.5-5% (w / v. By means of the method, the medicine performance is greatly improved, the specific surface area of artesunate is remarkably increased through the nanoscale particles, the water solubility and the dissolution rate of artesunate are greatly improved, the bioavailability is improved by 30%-50%, and the bioavailability of artesunate is improved by 30%-50%. The drug administration dosage is reduced while the curative effect is enhanced, the toxic and side effects are reduced, and the stability is excellent. The dispersing agent and the suspending aid have a synergistic effect and are combined with a nanocrystallization process, so that particles are effectively prevented from gathering and settling; the antioxidant is accurately proportioned, oxidative degradation of the medicine is inhibited, the medicine content is kept at 95% or above after the medicine is stored at normal temperature for 6 months, and the particle size change does not exceed 10%.

This invention relates to the field of medical antibacterial technology, and in particular to a rare-earth artemisinin derivative organic salt, its preparation method, and its application, with the general formula [Art-COO]. n RE n+ In the formula, Art represents an artemisinin derivative, RE represents a rare earth ion, and n represents the valence of the rare earth ion; artemisinin derivatives include artesunate, and rare earth ions include La... 3+ Ce 3+ One of them. This invention utilizes the above-mentioned rare-earth artemisinin derivative organic salt, its preparation method, and its application. The obtained organic salt retains the peroxide bridge structure of artesunate, while the carboxylate group (-COO) is present. ‑ The stable existence of coordination bonds between rare earth ions and artesunate allows rare earth ions to synergistically enhance the antibacterial effect, significantly reducing the minimum inhibitory concentration against a variety of pathogens, and thus having important application value in the field of medical anti-infection.

The invention discloses an application of forchlorfenuron (FCF) in the preparation of a medicine for treating malaria, and relates to the field of medicines for treating malaria. The invention belongs to the technical field of biological medicine. According to the invention, the in-vivo insecticidal effect of forchlorfenuron is observed by establishing a Plasmodium berghei (pb) ANKA strain infected mouse model. Observation indexes mainly include calculation of insect blood rate, anemia condition, spleen form, spleen index and other index detection. Results show that when the forchlorfenuron (as shown in the formula I) is independently used or combined with artesunate, the forchlorfenuron has a remarkable effect of killing the plasmodium, the infection rate of the plasmodium in red blood cells can be remarkably reduced, the degree of mouse spleen injury caused by plasmodium infection is improved, and then the anemia condition of the mouse is improved. The invention provides a new technical means for treating malaria, and forchlorfenuron has a wide application prospect in the aspect of treating parasitic infection.

The invention discloses application of artesunate in preparation of medicines and health care products for preventing and treating iron-deficiency anemia caused by iron absorption disorder and / or iron transport dysfunction, in-vitro experiments find that artesunate can target divalent metal transport protein (DMT1), DMT1 is oxidized through free radicals to form disulfide bonds, the space structure of DMT1 is changed, and the iron-deficiency anemia caused by iron absorption disorder and / or iron transport dysfunction is prevented. The iron transport function of the DMT1 protein is enhanced, so that the uptake of divalent iron by cells is effectively increased; animal experiments further prove that the artesunate can remarkably improve anemia symptoms of mice with iron-deficiency anemia, anemia related indexes of the mice are effectively recovered, and the iron content in red blood cells and livers is recovered to the normal level. In-vitro and in-vivo experiments prove the treatment effect of artesunate on iron-deficiency anemia, a new treatment scheme is provided for treatment of iron-deficiency anemia patients, and the indication types of artemisinin drugs are expanded.

Use of artesunate in the preparation of a medicament for preventing and treating anemia. In vitro experiments have shown that artesunate can enhance the iron transport function of the DMT1 protein to increase iron ion uptake. In addition, animal experiments have demonstrated that artesunate can significantly improve anemia symptoms in mice with iron-deficiency anemia, effectively restore anemia-related indicators, and even restore the iron content in red blood cells and the liver to a healthy level.